WEKO3
アイテム
{"_buckets": {"deposit": "3f4f06b7-4d86-4fe4-85a7-4a5533ec4943"}, "_deposit": {"created_by": 2, "id": "9597", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "9597"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00009597", "sets": ["30"]}, "author_link": ["38762", "38759", "38760", "38764", "38765", "38767", "38758", "38761", "38763", "38757", "38766", "38756"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "374", "bibliographicPageStart": "369", "bibliographicVolumeNumber": "13", "bibliographic_titles": [{"bibliographic_title": "Clinical Lung Cancer"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Epidermal growth factor receptor (EGFR) mutations are predictive of response to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Several methods have been used to detect EGFR mutations; however, it is not clear which is the most suitable for use in the clinic. In this study, we directly compare the clinical sensitivity and specificity of 3 PCR methods. We compared the 3 PCR methods (mutant-enriched PCR, PNA-LNA PCR, and PCR clamp) in patients with advanced NSCLC. A patient who showed sensitive mutations by at least 1 PCR method was treated with gefitinib. A patient who showed no sensitive mutations was treated with chemotherapy with cytotoxic agents. Fifty patients with advanced NSCLC previously untreated with EGFR-TKIs were enrolled in this trial. Seventeen patients were harboring EGFR mutations, 5 of whom showed discrepancies between the results of different PCR methods. All 5 patients responded to gefitinib. All patients harboring EGFR mutations received gefitinib treatment and 21 of 33 EGFR-mutation-negative patients received chemotherapy with cytotoxic agents. Median progression-free survival of the gefitinib group and the chemotherapy group were 8.2 and 5.9 months, respectively. We considered that all the discrepancies might be false negatives because the patients responded to gefitinib. To clarify the reason for the false negatives of each PCR method, and establish the clinical sensitivity and specificity of each PCR method, a large prospective clinical trial is warranted.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Clinical Lung Cancer, 13(5), pp.369-374; 2012", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.cllc.2012.01.008", "subitem_relation_type_select": "DOI"}}]}, "item_2_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://hdl.handle.net/10069/32640"}]}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2012 Elsevier Inc."}, {"subitem_rights": "NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Lung Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Lung Cancer, 13, 5(2012)"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15257304", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ikeda, Takaya"}], "nameIdentifiers": [{"nameIdentifier": "38756", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "38757", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "38758", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomonaga, Nanae"}], "nameIdentifiers": [{"nameIdentifier": "38759", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Doi, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "38760", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "38761", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iida, Tetsuya"}], "nameIdentifiers": [{"nameIdentifier": "38762", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motoshima, Kohei"}], "nameIdentifiers": [{"nameIdentifier": "38763", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizoguchi, Kosuke"}], "nameIdentifiers": [{"nameIdentifier": "38764", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagayasu, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "38765", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukamoto, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "38766", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "38767", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CLC13_369.pdf", "filesize": [{"value": "243.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 243100.0, "url": {"label": "CLC13_369.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/9597/files/CLC13_369.pdf"}, "version_id": "64aeb16b-488b-4d35-a662-25221476e915"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "EGFR mutations", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Mutant-enriched PCR", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-Small-cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "PCR invader", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/30240", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-01-16"}, "publish_date": "2013-01-16", "publish_status": "0", "recid": "9597", "relation": {}, "relation_version_is_last": true, "title": ["Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer"], "weko_shared_id": -1}
Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer
http://hdl.handle.net/10069/30240
http://hdl.handle.net/10069/302403213088e-3775-4971-a62f-2589863ca7dd
名前 / ファイル | ライセンス | アクション |
---|---|---|
CLC13_369.pdf (243.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-01-16 | |||||
タイトル | ||||||
タイトル | Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | EGFR mutations | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Mutant-enriched PCR | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-Small-cell lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | PCR invader | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ikeda, Takaya
× Ikeda, Takaya× Nakamura, Yoichi× Yamaguchi, Hiroyuki× Tomonaga, Nanae× Doi, Seiji× Nakatomi, Katsumi× Iida, Tetsuya× Motoshima, Kohei× Mizoguchi, Kosuke× Nagayasu, Takeshi× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Epidermal growth factor receptor (EGFR) mutations are predictive of response to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Several methods have been used to detect EGFR mutations; however, it is not clear which is the most suitable for use in the clinic. In this study, we directly compare the clinical sensitivity and specificity of 3 PCR methods. We compared the 3 PCR methods (mutant-enriched PCR, PNA-LNA PCR, and PCR clamp) in patients with advanced NSCLC. A patient who showed sensitive mutations by at least 1 PCR method was treated with gefitinib. A patient who showed no sensitive mutations was treated with chemotherapy with cytotoxic agents. Fifty patients with advanced NSCLC previously untreated with EGFR-TKIs were enrolled in this trial. Seventeen patients were harboring EGFR mutations, 5 of whom showed discrepancies between the results of different PCR methods. All 5 patients responded to gefitinib. All patients harboring EGFR mutations received gefitinib treatment and 21 of 33 EGFR-mutation-negative patients received chemotherapy with cytotoxic agents. Median progression-free survival of the gefitinib group and the chemotherapy group were 8.2 and 5.9 months, respectively. We considered that all the discrepancies might be false negatives because the patients responded to gefitinib. To clarify the reason for the false negatives of each PCR method, and establish the clinical sensitivity and specificity of each PCR method, a large prospective clinical trial is warranted. | |||||
書誌情報 |
Clinical Lung Cancer 巻 13, 号 5, p. 369-374, 発行日 2012-09 |
|||||
出版者 | ||||||
出版者 | Elsevier | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15257304 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.cllc.2012.01.008 | |||||
権利 | ||||||
権利情報 | © 2012 Elsevier Inc. | |||||
権利 | ||||||
権利情報 | NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Lung Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Lung Cancer, 13, 5(2012) | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
関係URI | ||||||
関連名称 | http://hdl.handle.net/10069/32640 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Clinical Lung Cancer, 13(5), pp.369-374; 2012 |